Global Gastroparesis Drugs Market 2026–2035 showing strong growth outlook

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Gastroparesis Drugs Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The gastroparesis drugs market size has demonstrated robust growth in recent years. It is forecast to rise from $5.7 billion in 2025 to $6.02 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.7%. This historical growth can be attributed to several factors, including the increasing diagnosis of diabetic gastroparesis, the longstanding application of prokinetic and antiemetic drugs, the growing prevalence of diabetes-related gastrointestinal disorders, the availability of both over-the-counter and prescription medications for symptom relief, and the expansion of gastroenterology care services.

The gastroparesis drugs market size is projected to experience robust expansion over the coming years. This market is anticipated to reach $7.37 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. Factors contributing to this growth during the projected timeframe include the increasing worldwide prevalence of diabetes, heightened recognition of gastroparesis as a chronic illness, a rising need for efficacious long-term symptom management, broader availability of specialized gastrointestinal treatment, and a continuous requirement for enhanced motility-improving therapies. Key developments expected within the forecast period involve an increased dependence on prokinetic agents for symptom relief, a surge in the adoption of combination drug therapies for gastroparesis, an escalating demand for prescription gastroparesis medications, an expansion of treatment strategies centered on symptoms, and a more widespread application of oral drug formulations for prolonged management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15812&type=smp

What Drivers Are Influencing The Gastroparesis Drugs Market?

The increasing prevalence of diabetes is anticipated to propel the growth of the gastroparesis drugs market. Diabetes is a chronic metabolic disorder characterized by elevated blood sugar levels, resulting from inadequate insulin production or impaired insulin utilization. The rising occurrence of diabetes is attributed to factors such as sedentary lifestyles, unhealthy dietary behaviors, genetic predisposition, urbanization, aging populations, and growing obesity rates. The gastroparesis drugs market supports diabetes care by offering medications that relieve common gastrointestinal complications associated with diabetic gastroparesis, including symptoms like nausea, vomiting, and delayed gastric emptying. For instance, in March 2024, the Office for Health Improvement & Disparities, a UK-based government department, reported that between March 2022 and March 2023, individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while type 2 diabetes patients saw a 21% increase, and the percentage achieving target HbA1c levels rose to 37.9%, which was the highest value ever reported by the National Diabetes Audit. Therefore, the increasing prevalence of diabetes is driving the growth of the gastroparesis drugs market.

What Major Segment Divisions Exist Within The Gastroparesis Drugs Market?

The gastroparesis drugs market covered in this report is segmented –

1) By Drug Type: Over-the-counter (OTC) Drugs, Prescription Drugs

2) By Drug Class: Prokinetic Agents, Antiemetic Drugs, Proton Pump Inhibitors, Other Drug Classes

3) By Disease Type: Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, Other Disease Types

4) By Route Of Administration: Oral, Injectables, Other Routes Of Administration

5) By Distribution Channel: Hospitals, Pharmacies, Clinics, E-commerce

Subsegments:

1) By Over-the-counter (OTC) Drugs: Antacids, Anti-Nausea Medications, Antiemetics, Digestive Enzyme Supplements

2) By Prescription Drugs: Prokinetic Agents, Antiemetic Drugs, Antibiotics, Antidepressants

How Are Trends Shaping The Direction Of The Gastroparesis Drugs Market?

Leading companies in the gastroparesis drugs market are dedicated to developing groundbreaking solutions, such as novel prokinetic therapies, to enhance gastric motility and alleviate symptoms. These novel prokinetic therapies are new medications specifically designed to stimulate and improve the natural movement of the stomach and intestines, aiding in more effective food passage. For example, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for the submission of its New Drug Application (NDA) for tradipitant, aimed at treating symptoms of gastroparesis. This approval concerns tradipitant, an investigational oral neurokinin-1 receptor antagonist, intended to address gastroparesis, a severe digestive disorder with significant unmet medical needs. This acceptance represents a pivotal regulatory achievement for Vanda as it proceeds with its efforts to gain marketing authorization for tradipitant for patients suffering from gastroparesis.

Which Companies Are Leading Innovation In The Gastroparesis Drugs Market?

Major companies operating in the gastroparesis drugs market are Evoke Pharma Inc., Takeda Pharmaceutical Inc., AbbVie Inc., Salix Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, AstraZeneca plc, Teva Pharmaceutical Inc., Bausch Health Companies Inc., Abbott Laboratories, GSK plc, Eisai Co. Ltd., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc., ANI Pharmaceuticals Inc., Cadila Pharmaceuticals, Cipla Ltd., Ipca Laboratories Ltd., Neurogastrx Inc., Processa Pharmaceuticals Inc.

Read the full gastroparesis drugs market report here:

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Gastroparesis Drugs Market?

North America was the largest region in the gastroparesis drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Gastroparesis Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15812&type=smp

Browse Through More Reports Similar to the Global Gastroparesis Drugs Market 2026, By The Business Research Company

Gastroparesis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-drugs-global-market-report

Gastrointestinal Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drugs-global-market

Gastroparesis Market Report 2026

https://www.thebusinessresearchcompany.com/report/gastroparesis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795